Hans Keirstead, a researcher at University of California, Irvine, is set to begin a small human trial of his embryonic stem cell treatment on patients with spinal cord injuries. The treatment is designed for patients within 14 days of suffering spinal cord injuries. In rat trials, paralyzed rats were injected with a stem cell formula. The paralyzed rats were able to walk six weeks later.
Stem Cell Therapeutics Corp. or the wishes to announce the acceptance and publication of the paper entitled “The Beta-hCG + Erythropoietin in Acute Stroke (BETAS) Study” by the journal “Stroke”, on March 8, 2010.
This paper was authored by Dr. Steven C. Cramer, from the University of California, Irvine, Dr. David Brown at Hoag Memorial Hospital Presbyterian, New Port Beach, Dr. Michael D. Hill of Foothills Hospital at the University of Calgary, and colleagues.
Dr. Allen Davidoff, VP of Product Development, commented as follows:
“The Stroke journal, published by the American Heart Association, is the top journal in the field of stroke
Image via Wikipedia
Complications and unanticipated side-effects that have slowed the progression of stem cell studies from the lab to the clinic could soon change, researchers say.
For a decade, stem cells have tantalized scientists and patients with their promise to regenerate damaged tissues and offer treatments for incurable diseases.
No one hears, however, about the individuals who died due to complications of surgery, said Dr. Hans Keirstead, a Canadian researcher who made a paralyzed rat walk back in 2004 by injecting its spinal cord with cells derived from human embryonic stem cells.
Keirstead’s lab at the University of California-Irvine just received approval
Frank LaFerla, left, Mathew Blurton-Jones and colleagues found that neural stem cells could be a potential treatment for advanced Alzheimer's disease
UC Irvine scientists have shown for the first time that neural stem cells can rescue memory in mice with advanced Alzheimer’s disease, raising hopes of a potential treatment for the leading cause of elderly dementia that afflicts 5.3 million people in the U.S.
Mice genetically engineered to have Alzheimer’s performed markedly better on memory tests a month after mouse neural stem cells were injected into their brains. The stem cells secreted a protein that created more neural connections, improving
Aileen Anderson and Brian Cummings led the pre-clinical studies for the neural stem cell treatment
A therapy developed by Aileen Anderson and Brian Cummings of UC Irvine’s Sue & Bill Gross Stem Cell Research Center in collaboration with researchers at StemCells Inc. will be the basis of the world’s first clinical trial using human neural stem cells to treat spinal cord injury.
Swissmedic, the Swiss regulatory agency for therapeutic products, has authorized a Phase I/II clinical trial for chronic spinal cord injury, cases in which inflammation has stabilized and recovery has reached a